Resverlogix Corp. (RVXCF)
USD 0.04
(0.0%)
USD 0.04
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2022 | 6.49 Million USD | -7.8% |
| 2021 | 7.04 Million USD | 0.0% |
| 2019 | 13.15 Million USD | -10.95% |
| 2018 | 14.77 Million USD | 1986.58% |
| 2017 | 708 Thousand USD | -98.54% |
| 2016 | 48.63 Million USD | 1.93% |
| 2015 | 47.71 Million USD | 6.66% |
| 2014 | 44.73 Million USD | 69.02% |
| 2013 | 26.46 Million USD | -0.71% |
| 2012 | 26.65 Million USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | -100.0% |
| 2008 | 4.83 Million USD | -60.07% |
| 2007 | 12.1 Million USD | -8.77% |
| 2006 | 13.26 Million USD | 0.0% |
| 2005 | - USD | -100.0% |
| 2004 | 26.1 Thousand USD | -42.94% |
| 2003 | 45.75 Thousand USD | 218.97% |
| 2002 | 14.34 Thousand USD | 0.0% |
| 2001 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q2 | 6.84 Million USD | 0.0% |
| 2023 Q3 | 6.77 Million USD | -1.11% |
| 2022 Q2 | 6.47 Million USD | -8.01% |
| 2022 Q3 | 6.16 Million USD | -4.83% |
| 2022 FY | 6.49 Million USD | -7.8% |
| 2022 Q1 | 7.03 Million USD | -0.01% |
| 2022 Q4 | 6.49 Million USD | 5.34% |
| 2021 FY | 7.04 Million USD | 0.0% |
| 2021 Q3 | 7.12 Million USD | -1.53% |
| 2021 Q4 | 7.04 Million USD | -1.15% |
| 2021 Q2 | 7.23 Million USD | 297.85% |
| 2021 Q1 | 1.81 Million USD | 0.0% |
| 2020 Q3 | 1.67 Million USD | -85.98% |
| 2020 Q1 | 13.15 Million USD | 1.45% |
| 2020 Q2 | 11.97 Million USD | -8.95% |
| 2019 FY | 13.15 Million USD | -10.95% |
| 2019 Q4 | 12.96 Million USD | 1.78% |
| 2019 Q3 | 12.74 Million USD | -27.58% |
| 2019 Q1 | 14.77 Million USD | 2.0% |
| 2019 Q2 | 17.59 Million USD | 19.1% |
| 2018 Q3 | 18.76 Million USD | -34.49% |
| 2018 Q4 | 14.48 Million USD | -22.81% |
| 2018 Q1 | 708 Thousand USD | 0.0% |
| 2018 Q2 | 28.64 Million USD | 3945.62% |
| 2018 FY | 14.77 Million USD | 1986.58% |
| 2017 Q1 | 48.63 Million USD | -2.15% |
| 2017 FY | 708 Thousand USD | -98.54% |
| 2017 Q4 | - USD | -100.0% |
| 2017 Q2 | 54.77 Million USD | 12.62% |
| 2017 Q3 | 53.32 Million USD | -2.66% |
| 2016 Q1 | 47.71 Million USD | 15.04% |
| 2016 Q4 | 49.7 Million USD | 5.63% |
| 2016 Q3 | 47.05 Million USD | -0.11% |
| 2016 Q2 | 47.11 Million USD | -1.27% |
| 2016 FY | 48.63 Million USD | 1.93% |
| 2015 Q3 | 43.52 Million USD | 2.24% |
| 2015 Q2 | 42.57 Million USD | -4.84% |
| 2015 FY | 47.71 Million USD | 6.66% |
| 2015 Q1 | 44.73 Million USD | 8.42% |
| 2015 Q4 | 41.47 Million USD | -4.71% |
| 2014 Q1 | 26.46 Million USD | 3.45% |
| 2014 FY | 44.73 Million USD | 69.02% |
| 2014 Q3 | 45.87 Million USD | 68.87% |
| 2014 Q2 | 27.16 Million USD | 2.64% |
| 2014 Q4 | 41.26 Million USD | -10.06% |
| 2013 FY | 26.46 Million USD | -0.71% |
| 2013 Q1 | 26.65 Million USD | 52.84% |
| 2013 Q2 | 26.59 Million USD | -0.24% |
| 2013 Q3 | 26.74 Million USD | 0.58% |
| 2013 Q4 | 25.58 Million USD | -4.34% |
| 2012 FY | 26.65 Million USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q3 | 17.13 Million USD | 0.0% |
| 2012 Q4 | 17.44 Million USD | 1.79% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2009 Q3 | 4.81 Million USD | 0.41% |
| 2009 FY | - USD | -100.0% |
| 2009 Q4 | - USD | -100.0% |
| 2009 Q2 | 4.79 Million USD | -0.76% |
| 2009 Q1 | 4.83 Million USD | -5.77% |
| 2008 FY | 4.83 Million USD | -60.07% |
| 2008 Q4 | 5.12 Million USD | -1.84% |
| 2008 Q3 | 5.22 Million USD | -55.69% |
| 2008 Q2 | 11.78 Million USD | -2.58% |
| 2008 Q1 | 12.1 Million USD | -8.72% |
| 2007 FY | 12.1 Million USD | -8.77% |
| 2007 Q4 | 13.25 Million USD | -17.12% |
| 2007 Q2 | 23.53 Million USD | 77.38% |
| 2007 Q1 | 13.26 Million USD | -15.34% |
| 2007 Q3 | 15.99 Million USD | -32.01% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q1 | - USD | -100.0% |
| 2006 FY | 13.26 Million USD | 0.0% |
| 2006 Q4 | 15.66 Million USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2005 Q1 | 26.1 Thousand USD | -20.43% |
| 2005 Q4 | 7441.74 USD | -47.81% |
| 2005 FY | - USD | -100.0% |
| 2005 Q2 | 20.43 Thousand USD | -21.74% |
| 2005 Q3 | 14.25 Thousand USD | -30.22% |
| 2004 Q1 | 45.75 Thousand USD | -13.13% |
| 2004 FY | 26.1 Thousand USD | -42.94% |
| 2004 Q4 | 32.8 Thousand USD | -17.15% |
| 2004 Q3 | 39.6 Thousand USD | -5.23% |
| 2004 Q2 | 41.78 Thousand USD | -8.67% |
| 2003 Q3 | 21.44 Thousand USD | 8.7% |
| 2003 Q2 | 19.72 Thousand USD | 37.52% |
| 2003 Q4 | 52.67 Thousand USD | 145.65% |
| 2003 FY | 45.75 Thousand USD | 218.97% |
| 2003 Q1 | 14.34 Thousand USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 FY | 14.34 Thousand USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 84.246% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -57.474% |
| SQZ Biotechnologies Company | 27.47 Million USD | 76.371% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 85.034% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 78.194% |
| Mesoblast Limited | 118.7 Million USD | 94.532% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -584.509% |
| Genus plc | 233.1 Million USD | 97.215% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -121.507% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -383.111% |
| Marizyme, Inc. | 18.71 Million USD | 65.321% |
| ContraFect Corporation | 2.88 Million USD | -125.304% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -765.467% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -4690.866% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -348.794% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -179.068% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -14.715% |
| MultiCell Technologies, Inc. | 202.58 USD | -3204066.255% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 88.709% |
| EV Biologics, Inc. | 1.49 Million USD | -334.253% |
| Q BioMed Inc. | 4.1 Million USD | -57.933% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 80.39% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -930.192% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -428.428% |
| Biomind Labs Inc. | 735.54 Thousand USD | -782.478% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 96.216% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 50.058% |
| Skye Bioscience, Inc. | 4.61 Million USD | -40.642% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -630.916% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -4486.696% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -10.559% |
| IMV Inc. | 28.88 Million USD | 77.527% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -25138.151% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -187.418% |
| GB Sciences, Inc. | 1.75 Million USD | -268.952% |
| Alpha Cognition Inc. | 1.22 Million USD | -431.887% |
| HST Global, Inc. | 98.31 Thousand USD | -6501.979% |
| CSL Limited | 12.18 Billion USD | 99.947% |
| Halberd Corporation | 150 Thousand USD | -4227.333% |
| Enzolytics Inc. | 996.33 Thousand USD | -551.486% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -1259.372% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -2439.594% |
| argenx SE | 20 Million USD | 67.545% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 85.753% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -139.635% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -63381.663% |
| Genscript Biotech Corporation | 417.73 Million USD | 98.446% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -3135.535% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -170.715% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -2730.9% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 90.404% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -114.494% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -1704.509% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 68.069% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -4266.516% |
| BioStem Technologies, Inc. | 4.71 Million USD | -37.772% |
| ONE Bio Corp. | 19.71 Million USD | 67.076% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -2494.511% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -2509.762% |
| Agentix Corp. | 50 Thousand USD | -12882.0% |
| LadRx Corporation | 33.6 Thousand USD | -19215.003% |
| Cell Source, Inc. | 9.25 Million USD | 29.859% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -758.366% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -758.366% |
| NovAccess Global Inc. | 2.19 Million USD | -195.062% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 8.226% |
| Itoco Inc. | 228.37 Thousand USD | -2742.23% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -2976.668% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -30.263% |
| Kadimastem Ltd | 891.22 Thousand USD | -628.323% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -1515.283% |
| CytoDyn Inc. | 30.07 Million USD | 78.418% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -1240.329% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -1744.836% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 16.994% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -5198.776% |
| Rebus Holdings, Inc. | 310 Thousand USD | -1993.871% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -37.077% |
| International Stem Cell Corporation | 4.17 Million USD | -55.361% |
| Bioxytran, Inc. | 1.92 Million USD | -237.195% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -10300.077% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -197.629% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 21.946% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 24.391% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -317.299% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -2322.015% |
| Neutra Corp. | 54.15 Thousand USD | -11885.745% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -254.699% |
| PureTech Health plc | 25.51 Million USD | 74.557% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -430.213% |
| IXICO plc | 472.02 Thousand USD | -1275.145% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 58.125% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 89.575% |
| CSL Limited | 12.18 Billion USD | 99.947% |
| Cellectis S.A. | 92.77 Million USD | 93.004% |